

Jeremy L Jenkins

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2296162/publications.pdf>

Version: 2024-02-01

75
papers

6,004
citations

87723

38
h-index

74018

75
g-index

90
all docs

90
docs citations

90
times ranked

6232
citing authors

#	ARTICLE	IF	CITATIONS
1	DRUG-seq Provides Unbiased Biological Activity Readouts for Neuroscience Drug Discovery. ACS Chemical Biology, 2022, 17, 1401-1414.	1.6	7
2	CYP27A1-dependent anti-melanoma activity of limonoid natural products targets mitochondrial metabolism. Cell Chemical Biology, 2021, 28, 1407-1419.e6.	2.5	11
3	Learning epistatic gene interactions from perturbation screens. PLoS ONE, 2021, 16, e0254491.	1.1	5
4	CPSF3-dependent pre-mRNA processing as a druggable node in AML and Ewing's sarcoma. Nature Chemical Biology, 2020, 16, 50-59.	3.9	59
5	Phenotypic landscape of intestinal organoid regeneration. Nature, 2020, 586, 275-280.	13.7	162
6	Systematic Chemogenetic Library Assembly. Cell Chemical Biology, 2020, 27, 1124-1129.	2.5	37
7	Ten simple rules to power drug discovery with data science. PLoS Computational Biology, 2020, 16, e1008126.	1.5	14
8	Benchmarking network algorithms for contextualizing genes of interest. PLoS Computational Biology, 2019, 15, e1007403.	1.5	7
9	Discovery of a ZIP7 inhibitor from a Notch pathway screen. Nature Chemical Biology, 2019, 15, 179-188.	3.9	46
10	Growth-restricting effects of siRNA transfections: a largely deterministic combination of off-target binding and hybridization-independent competition. Nucleic Acids Research, 2018, 46, 9309-9320.	6.5	7
11	DRUG-seq for miniaturized high-throughput transcriptome profiling in drug discovery. Nature Communications, 2018, 9, 4307.	5.8	133
12	Indolyl-Pyridinyl-Propenone-Induced Methuosis through the Inhibition of PIKFYVE. ACS Omega, 2018, 3, 6097-6103.	1.6	22
13	Recurrent ubiquitin B silencing in gynecological cancers establishes dependence on ubiquitin C. Journal of Clinical Investigation, 2017, 127, 4554-4568.	3.9	21
14	Data-Driven Derivation of an Informer Compound Set for Improved Selection of Active Compounds in High-Throughput Screening. Journal of Chemical Information and Modeling, 2016, 56, 1622-1630.	2.5	14
15	Evidence-Based and Quantitative Prioritization of Tool Compounds in Phenotypic Drug Discovery. Cell Chemical Biology, 2016, 23, 862-874.	2.5	52
16	Identifying compound efficacy targets in phenotypic drug discovery. Drug Discovery Today, 2016, 21, 82-89.	3.2	127
17	Causal Network Models for Predicting Compound Targets and Driving Pathways in Cancer. Journal of Biomolecular Screening, 2014, 19, 791-802.	2.6	23
18	Translation of off-target effects: prediction of ADRs by integrated experimental and computational approach. Toxicology Research, 2014, 3, 433-444.	0.9	11

#	ARTICLE	IF	CITATIONS
19	Using Information from Historical High-Throughput Screens to Predict Active Compounds. <i>Journal of Chemical Information and Modeling</i> , 2014, 54, 1880-1891.	2.5	79
20	Target identification for a Hedgehog pathway inhibitor reveals the receptor GPR39. <i>Nature Chemical Biology</i> , 2014, 10, 343-349.	3.9	53
21	Rethinking cellular drug response. <i>Nature Chemical Biology</i> , 2013, 9, 669-670.	3.9	7
22	Biodiversity of small molecules – a new perspective in screening set selection. <i>Drug Discovery Today</i> , 2013, 18, 674-680.	3.2	51
23	The Multidimensional Perturbation Value: A Single Metric to Measure Similarity and Activity of Treatments in High-Throughput Multidimensional Screens. <i>Journal of Biomolecular Screening</i> , 2013, 18, 367-377.	2.6	30
24	Determination of minimal transcriptional signatures of compounds for target prediction. <i>Eurasip Journal on Bioinformatics and Systems Biology</i> , 2012, 2012, 2.	1.4	7
25	Rethinking Molecular Similarity: Comparing Compounds on the Basis of Biological Activity. <i>ACS Chemical Biology</i> , 2012, 7, 1399-1409.	1.6	181
26	Large-scale QSAR in Target Prediction and Phenotypic HTS Assessment. <i>Molecular Informatics</i> , 2012, 31, 508-514.	1.4	9
27	Large-scale prediction and testing of drug activity on side-effect targets. <i>Nature</i> , 2012, 486, 361-367.	13.7	782
28	Activity-Aware Clustering of High Throughput Screening Data and Elucidation of Orthogonal Structure-Activity Relationships. <i>Journal of Chemical Information and Modeling</i> , 2011, 51, 3158-3168.	2.5	20
29	From in silico target prediction to multi-target drug design: Current databases, methods and applications. <i>Journal of Proteomics</i> , 2011, 74, 2554-2574.	1.2	243
30	Computational methods for early predictive safety assessment from biological and chemical data. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 1497-1511.	1.5	28
31	Recent trends and observations in the design of high-quality screening collections. <i>Future Medicinal Chemistry</i> , 2011, 3, 751-766.	1.1	55
32	A lead discovery strategy driven by a comprehensive analysis of proteases in the peptide substrate space. <i>Protein Science</i> , 2010, 19, 2096-2109.	3.1	7
33	Fishing for neuroactive compounds. <i>Nature Chemical Biology</i> , 2010, 6, 172-173.	3.9	14
34	SPREAD – exploiting chemical features that cause differential activity behavior. <i>Statistical Analysis and Data Mining</i> , 2009, 2, 115-122.	1.4	1
35	Chemogenomics: Looking at biology through the lens of chemistry. <i>Statistical Analysis and Data Mining</i> , 2009, 2, 149-160.	1.4	10
36	Plate-Based Diversity Selection Based on Empirical HTS Data to Enhance the Number of Hits and Their Chemical Diversity. <i>Journal of Biomolecular Screening</i> , 2009, 14, 690-699.	2.6	67

#	ARTICLE	IF	CITATIONS
37	Use of Ligand Based Models for Protein Domains To Predict Novel Molecular Targets and Applications To Triage Affinity Chromatography Data. <i>Journal of Proteome Research</i> , 2009, 8, 2575-2585.	1.8	20
38	How Similar Are Similarity Searching Methods? A Principal Component Analysis of Molecular Descriptor Space. <i>Journal of Chemical Information and Modeling</i> , 2009, 49, 108-119.	2.5	268
39	Mapping Adverse Drug Reactions in Chemical Space. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 3103-3107.	2.9	156
40	Gaining Insight into Off-Target Mediated Effects of Drug Candidates with a Comprehensive Systems Chemical Biology Analysis. <i>Journal of Chemical Information and Modeling</i> , 2009, 49, 308-317.	2.5	161
41	Knowledge-Based Virtual Screening: Application to the MDM4/p53 Protein-Protein Interaction. <i>Methods in Molecular Biology</i> , 2009, 575, 173-194.	0.4	20
42	Chemogenomic Analysis of Safety Profiling Data. <i>Methods in Molecular Biology</i> , 2009, 575, 207-223.	0.4	9
43	Blocking binding of <i>Bacillus thuringiensis</i> Cry1Aa to <i>Bombyx mori</i> cadherin receptor results in only a minor reduction of toxicity. <i>BMC Biochemistry</i> , 2008, 9, 3.	4.4	11
44	Integrating high-content screening and ligand-target prediction to identify mechanism of action. <i>Nature Chemical Biology</i> , 2008, 4, 59-68.	3.9	332
45	“Virtual Fragment Linking”: An Approach To Identify Potent Binders from Low Affinity Fragment Hits. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 2481-2491.	2.9	39
46	Ligand-Target Prediction Using Winnow and Naive Bayesian Algorithms and the Implications of Overall Performance Statistics. <i>Journal of Chemical Information and Modeling</i> , 2008, 48, 2313-2325.	2.5	92
47	Chemogenomic Data Analysis: Prediction of Small-Molecule Targets and the Advent of Biological Fingerprints. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2007, 10, 719-731.	0.6	97
48	“Plate Cherry Picking”: A Novel Semi-Sequential Screening Paradigm for Cheaper, Faster, Information-Rich Compound Selection. <i>Journal of Biomolecular Screening</i> , 2007, 12, 320-327.	2.6	33
49	Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off-Target Effects from Chemical Structure. <i>ChemMedChem</i> , 2007, 2, 861-873.	1.6	287
50	Clustering and Rule-Based Classifications of Chemical Structures Evaluated in the Biological Activity Space. <i>Journal of Chemical Information and Modeling</i> , 2007, 47, 325-336.	2.5	50
51	Understanding False Positives in Reporter Gene Assays: In Silico Chemogenomics Approaches To Prioritize Cell-Based HTS Data. <i>Journal of Chemical Information and Modeling</i> , 2007, 47, 1319-1327.	2.5	66
52	Modeling Promiscuity Based on In Vitro Safety Pharmacology Profiling Data. <i>ChemMedChem</i> , 2007, 2, 874-880.	1.6	169
53	Flexible 3D pharmacophores as descriptors of dynamic biological space. <i>Journal of Molecular Graphics and Modelling</i> , 2007, 26, 622-633.	1.3	47
54	Enrichment of High-Throughput Screening Data with Increasing Levels of Noise Using Support Vector Machines, Recursive Partitioning, and Laplacian-Modified Naive Bayesian Classifiers. <i>Journal of Chemical Information and Modeling</i> , 2006, 46, 193-200.	2.5	110

#	ARTICLE	IF	CITATIONS
55	Prediction of Biological Targets for Compounds Using Multiple-Category Bayesian Models Trained on Chemogenomics Databases. <i>Journal of Chemical Information and Modeling</i> , 2006, 46, 1124-1133.	2.5	315
56	Chapter 9 Molecular Similarity: Advances in Methods, Applications and Validations in Virtual Screening and QSAR. <i>Annual Reports in Computational Chemistry</i> , 2006, 2, 141-168.	0.9	10
57	Bridging Chemical and Biological Space: A "Target Fishing" Using 2D and 3D Molecular Descriptors. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 6802-6810.	2.9	184
58	"Bayes Affinity Fingerprints" Improve Retrieval Rates in Virtual Screening and Define Orthogonal Bioactivity Space: When Are Multitarget Drugs a Feasible Concept?. <i>Journal of Chemical Information and Modeling</i> , 2006, 46, 2445-2456.	2.5	125
59	In silico target fishing: Predicting biological targets from chemical structure. <i>Drug Discovery Today: Technologies</i> , 2006, 3, 413-421.	4.0	155
60	Streamlining lead discovery by aligning in silico and high-throughput screening. <i>Current Opinion in Chemical Biology</i> , 2006, 10, 343-351.	2.8	85
61	A 3D Similarity Method for Scaffold Hopping from Known Drugs or Natural Ligands to New Chemotypes. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 6144-6159.	2.9	126
62	Unexpected Binding Mode for 2'-Phosphoadenosine-Based Nucleotide Inhibitors in Complex with Human Angiogenin Revealed by Heteronuclear NMR Spectroscopy. <i>Biochemistry</i> , 2003, 42, 11137-11149.	1.2	11
63	Identification of Small-Molecule Inhibitors of Human Angiogenin and Characterization of Their Binding Interactions Guided by Computational Docking. <i>Biochemistry</i> , 2003, 42, 6674-6687.	1.2	34
64	Inhibition of mammalian ribonucleases by endogenous adenosine dinucleotides. <i>Biochemical and Biophysical Research Communications</i> , 2003, 300, 81-86.	1.0	18
65	A small-molecule inhibitor of the ribonucleolytic activity of human angiogenin that possesses antitumor activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 10066-10071.	3.3	103
66	Virtual screening to enrich hit lists from high-throughput screening: A case study on small-molecule inhibitors of angiogenin. <i>Proteins: Structure, Function and Bioinformatics</i> , 2002, 50, 81-93.	1.5	75
67	Mutations at the arginine residues in the ± 8 loop of <i>Bacillus thuringiensis</i> δ -endotoxin Cry1Ac affect toxicity and binding to <i>Manduca sexta</i> and <i>Lymantria dispar</i> aminopeptidase N. <i>FEBS Letters</i> , 2001, 497, 108-112.	1.3	20
68	Cleavage of 3',5'-Pyrophosphate-Linked Dinucleotides by Ribonuclease A and Angiogenin. <i>Biochemistry</i> , 2001, 40, 10262-10272.	1.2	29
69	Plasma lipases and lipid transfer proteins increase phospholipid but not free cholesterol transfer from lipid emulsion to high density lipoproteins. <i>BMC Biochemistry</i> , 2001, 2, 1.	4.4	8
70	Binding specificity of <i>Bacillus thuringiensis</i> Cry1Aa for purified, native <i>Bombyx mori</i> aminopeptidase N and cadherin-like receptors. <i>BMC Biochemistry</i> , 2001, 2, 12.	4.4	29
71	Isolation and partial characterization of gypsy moth BTR-270, an anionic brush border membrane glycoconjugate that binds <i>Bacillus thuringiensis</i> Cry1A toxins with high affinity. <i>Archives of Insect Biochemistry and Physiology</i> , 2001, 46, 186-200.	0.6	71
72	Role of two arginine residues in domain II, loop 2 of Cry1Ab and Cry1Ac <i>Bacillus thuringiensis</i> δ -endotoxin in toxicity and binding to <i>Manduca sexta</i> and <i>Lymantria dispar</i> aminopeptidase N. <i>Molecular Microbiology</i> , 2000, 38, 289-298.	1.2	30

#	ARTICLE	IF	CITATIONS
73	Bivalent Sequential Binding Model of a <i>Bacillus thuringiensis</i> Toxin to Gypsy Moth Aminopeptidase N Receptor. <i>Journal of Biological Chemistry</i> , 2000, 275, 14423-14431.	1.6	119
74	Exploring the Mechanism of Action of Insecticidal Proteins by Genetic Engineering Methods. , 2000, 22, 33-54.		17
75	Binding of <i>Bacillus thuringiensis</i> Cry1Ac toxin to <i>Manduca sexta</i> aminopeptidase-N receptor is not directly related to toxicity. <i>FEBS Letters</i> , 1999, 462, 373-376.	1.3	57